Invivyd Elects Two New Independent Members to its Board of Directors

Core Insights - Invivyd, Inc. has elected two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, to its Board of Directors during a period of significant growth for the company [1][2] - The company is focused on commercializing its first product and utilizing its proprietary tools for variant analysis and predictive modeling to develop advanced antibody candidates [2][6] - Invivyd has received emergency use authorization (EUA) from the U.S. FDA for its first monoclonal antibody (mAb) aimed at providing protection against COVID-19 for certain immunocompromised individuals [2][6] Company Overview - Invivyd, Inc. is a biopharmaceutical company dedicated to protecting against serious viral infectious diseases, starting with SARS-CoV-2 [6] - The company's INVYMAB™ platform integrates advanced viral surveillance and predictive modeling with antibody engineering to rapidly generate new mAbs [6] - The company aims to provide ongoing protection to vulnerable populations against evolving viral threats [2][6] New Board Members - Dr. Srishti Gupta brings over 20 years of healthcare experience, including 18 years at McKinsey & Company, and currently serves on the Board of Directors at Idorsia Pharmaceuticals [3] - Kevin F. McLaughlin has over 40 years of financial and operational management experience, previously serving as CFO of Acceleron Pharma, and currently holds positions on several other boards [4][5] Strategic Importance - The addition of Dr. Gupta and Mr. McLaughlin is seen as crucial for Invivyd as it transitions into a commercial organization and seeks to leverage its innovative platform for future growth [2][3][4] - The company is positioned to address the ongoing challenges posed by COVID-19, particularly for immunocompromised populations, through its mAb candidates [2][6]